Objective
Influenza epidemics remain a burden to both human heath and national economies, as witnessed by the recent advance of pathogenic avian H5N1 influenza virus. While the numbers of human deaths in Europe have remained relatively low, the presence of such cases in Turkey demonstrates the danger posed by this virus. Now that the avian H5N1 has been detected in wild birds in numerous European countries, the PANFLUVAC consortium is committed to creating an efficacious vaccine against this virus, to provide strong protection in a pandemic situation.
The overall aim of PANFLUVAC is to construct vaccine delivery systems for intranasal and parenteral vaccines. New H5N1 vaccines are to be based on well-established virosome technology - proven its worth for efficacious interpandemic vaccines - as well as whole virus vaccines. This will permit comparison of the intranasal virosomal vaccine with whole virus vaccine. The vaccine potency will be enhanced by novel adjuvants targeting dendritic cells, offering both antigen spa ring potential and immunopotentiation characteristics. Both ISCOMs and lipopeptide adjuvants are already proven immunopotentiators, biosafe for humans. Certain of these have been employed with experimental influenza vaccines, which allows the new H5N1 vaccines to be fast-tracked in their development. Accordingly, PANFLUVAC will generate the first H5N1 vaccine within the first 18 months of the project.
The PANFLUVAC project is also designed to facilitate rapid modification of the vaccine in the face of virus drift. Within the pre-clinical evaluation, the new vaccines will be tested for the degree of heterotypic cross protection they offer. PANFLUVAC offers a generic vaccine development system to provide safe and efficacious vaccines against influenza, fitting with the "Community Influenza Pandemic Preparedness and Response Planning".
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences zoology ornithology
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences public health epidemiology pandemics
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-SSP-5-B-INFLUENZA
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
BERN
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.